Posts

SenzaGen presenterar på Unicorn Summit den 7 mars 2017

SenzaGens vd Anki Malmborg Hager kommer att presentera bolagets spännande utveckling vid Vator Securities Unicorn Summit den 7 mars 2017.

Presentationen kommer beskriva hur företaget kommersialiserar och vidareutvecklar sina genombaserade tester (GARD), vilka kan bedöma om kemikalier vi kommer i kontakt med i vår vardag är allergiframkallande – ett ständigt ökande problem.  Testerna bygger på hur 200 gener i mänskliga celler reagerar på det ämnen som testas, vilket innebär att de är betydligt mer tillförlitliga och ger mer information än dagens analysmetoder och kan minska behovet av försöksdjur.
– Vårt test har en tillförlitlighet på 90 procent, medan djurförsök hamnade runt 75 procent, konstaterar Anki Mamborg Hager, vd för Senzagen.

Unicorn Summit är en kapitalmarknadsdag som anordnas av Vator Sercurities för att sammanföra några av de mest innovativa och snabbväxande svenska life science-bolagen med investerare. För mer information och anmälan till arrangemanget, se www.vatorsecurities.se


För mer information:

Anki Malmborg Hager, VD, SenzaGen AB
Email: amh@senzagen.com
Tel: +46 768 284822

Om SenzaGen
SenzaGen gör det möjligt att ersätta djurförsök med genetiska tester i provrör för att bedöma om de kemikalier vi kommer i kontakt med i vår vardag är allergiframkallande. Det kan till exempel handla om kosmetika, läkemedel, livsmedel och färgämnen. Bolagets patentskyddade tester är de mest tillförlitliga på marknaden och ger mer information än traditionella utvärderingsmetoder. Testerna säljs i egen regi i Sverige och USA, och genom partners i flera andra länder. De närmaste åren kommer bolaget expandera geografiskt, knyta till sig fler distributionspartners och lansera nya, unika tester. SenzaGen har sitt huvudkontor i Lund och dotterbolag i San Francisco, USA. För mer information, besök www.senzagen.com.

Gardair Gardpotency gardskin

SenzaGen´s share issue oversubscribed – raises MSEK 44

SenzaGen has just completed a share issue to accelerate the company’s rapidly growing revenues, scale up the sales organization, complete ongoing validation processes and develop new tests in the GARD portfolio. The interest has been overwhelming which is why the Company, at an Extraordinary General Meeting on Monday, October 5, 2015 decided to extend the offer from MSEK 25 to 44. Vator Securities acted financial advisor regarding the share issue.

“The interest regarding our share issue has exceeded all expectations. It is an acknowledgment of the superiority of SenzaGens test, and the need for animal free allergy tests in the market”, says Anki Malmborg Hager, CEO at SenzaGen.

With their base at Medicon Village in Lund, SenzaGen develops and implements animal free allergy tests of chemicals and proteins, especially for the cosmetic and pharmaceutical industry. SenzaGen’s test GARD (Genomic Allergen Rapid Detection) is based on more than 15 years of research and measures significantly more parameters than existing tests on the market. It makes GARD a much safer and more effective test than other options. GARD eliminates the need for animal testing and enables customers to develop and provide safer consumer products and to offer their employees a better working environment.

SenzaGen’s original ambition was to bring in MSEK 25. As a result of the great interest in the Company, it was decided at an Extraordinary General Meeting on Monday, October 5, 2015 to increase the share issue to MSEK 44, even if the interest was much higher. The proceeds will primarily finance the scaling up of the sales organization, validation process and the development of new tests in the GARD portfolio. In addition to the financing and development of the operational business, SenzaGen will also aim at listing the company on First North during 2017.

“As the interest for our GARD products is growing, we are also aiming at listing the company on First North in order to facilitate and finance the continued expansion and development internationally”, says Anki Malmborg Hager.

Vator Securities acted financial advisor.

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Mail: amh@senzagen.com
Phone: +46 768 284822.

Lund university

SenzaGen AB attracts financial support from LU Innovation System AB.

LU Innovation System AB (LUIS) has since 1999 been involved in spinning out 69 companies based on research from Lund University. The portfolio has now increased by the investment in SenzaGen AB.

“We have a strong connection to Lund University and the investment by LUIS acknowledges our work and provides us with the ability to take the next important steps in our commercialization strategy,” says Anki Malmborg Hager, CEO of SenzaGen AB.

“We are very pleased of being a partner in Senzagen, which we believe has a great commercial potential. The fact that their technology can replace animal experiments doesn´t make it worse”, says Linus Wiebe, Innovation Director Lund University and CEO LU Innovation System.

The company´s first product, a skin sensitization test of chemicals, is already on the market, and the company is working on next generation products that will address other types of sensitizers and other routes of exposure. Based on the demand from the market the company is now gearing up its commercial operations and prepares for the launch of further products.

For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
anki.malmborg.hager@senzagen.com
+46 768 284822

Linus Wiebe, Director of Innovation, LU Innovation Systems AB
linus.wiebe@innovation.lu.se
0733- 451 240